India’s Anesiva Loses Adlea, Zingo Painkillers From Market
This article was originally published in PharmAsia News
Executive Summary
A Phase III trial failed to support India-based Anesiva's Adlea (capsaicin) painkiller at the same time the firm said it would withdraw another painkiller, Zingo (lidocaine), from the U.S. market. The twin moves, according to an analyst, endanger the company's financial future. The trial showed Adlea failed to meet the main goal of the trial, Anesiva said. It withdrew Zingo because of problems with the shelf life of the drug caused by manufacturing difficulties, Anesiva said. The company said it still seeks to form a partnership with another firm on both drugs. Resurrecting Zingo would take at least a year and millions of dollars, the analyst said. (Click here for more
You may also be interested in...
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.